A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
Imatinib is a member of a new class of drugs known as signal transduction inhibitors. The
purpose of this study is to evaluate the efficacy, safety and tolerability of imatinib in the
treatment of rheumatoid arthritis in combination with methotrexate in patients who do not
respond satisfactorily to standard treatment, e.g. methotrexate.